Temporal variation in CB2R levels following T lymphocyte activation: Evidence that cannabinoids modulate CXCL12-induced chemotaxis

International Immunopharmacology

Volumn 7, Issue 3, 2007, Pages 360-371

  Coopman, Karen ^a   Smith, Laura D ^a   Wright, Karen L ^a   Ward, Stephen G ^a  

^a University of Bath   (United Kingdom)

Author keywords

Cannabinoid; Migration; Receptors; T lymphocyte

Indexed keywords

CANNABINOID; CANNABINOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STROMAL CELL DERIVED FACTOR 1; 1,1 DIMETHYLBUTYL 1 DEOXY DELTA(9) THC; 1,1-DIMETHYLBUTYL-1-DEOXY-DELTA(9)-THC; 2 ARACHIDONOYLGLYCEROL; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; ACYLGLYCEROL LIPASE; ALPHA CHEMOKINE; AMIDASE; AMIDE; ANANDAMIDE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 2 RECEPTOR; FATTY ACID AMIDASE; FATTY-ACID AMIDE HYDROLASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CELL ACTIVATION; CELL LINE; CELL MIGRATION; CHEMOTAXIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; ADULT; CELL STRAIN HT29; CHEMISTRY; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PHOSPHORYLATION;

ADULT; AMIDOHYDROLASES; ARACHIDONIC ACIDS; CANNABINOIDS; CHEMOKINES, CXC; CHEMOTAXIS, LEUKOCYTE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCERIDES; HT29 CELLS; HUMANS; MONOACYLGLYCEROL LIPASES; PHOSPHORYLATION; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 33846583671     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.11.008     Document Type: Article

References (68)

1. Klein T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5 (2005) 400-411
2. Cabral G.A., and Dove Pettit D.A. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 83 (1998) 116-123
3. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
4. Mechoulam R., Ben Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
5. Bisogno T., Ligresti A., and Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 81 (2005) 224-238
6. Goparaju S.K., Ueda N., Yamaguchi H., and Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 422 (1998) 69-73
7. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99 (2002) 0819-10824
8. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Nature 346 (1990) 561-564
9. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
10. Bayewitch M., Vidor-Reiss T., Levy R., Barg J., Mechoulam R., and Vogel Z. The peripheral cannabinoid receptor: adenylate-cyclase inhibition and G-protein coupling. FEBS Lett 375 (1995) 143-147
11. Howlett A.C., and Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 108 (2000) 53-70
12. 1. Biochem J 312 (1995) 637-641
13. Galve-Roperh I., Rueda D., Gomez D.P., Velasco G., and Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62 (2002) 1385-1392
14. Wartmann M., Campbell D., Subramanian A., Burstein S.H., and Davis R.J. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. FEBS Lett 359 (1995) 133-136
15. De Petrocellis L., Harrison S., Bisogno T., Tognetto M., Brandi I., Smith G.D., et al. The vanilloid receptor (VR1)-mediated effects of anandamide are potently enhanced by the cAMP-dependent protein kinase. J Neurochem 77 (2001) 1660-1663
16. Wiley J.L., and Martin B.R. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. Chem Phys Lipids 121 (2002) 57-63
17. Baker D., Pryce G., Davies W.L., and Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27 (2006) 1-4
18. Croxford J.L., and Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?. J Neuroimmunol 166 (2005) 3-18
19. Di Marzo V., Bifulco M., and De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3 (2004) 771-784
20. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232 (1995) 54-61
21. Kishimoto S., Gokoh M., Oka S., Muramatsu M., Kajiwara T., Waku K., et al. 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 278 (2003) 24469-24475
22. Jorda M.A., Lowenberg B., and Delwel R. The peripheral cannabinoid receptor CB2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. Blood 101 (2003) 1336-1343
23. Oka S., Ikeda S., Kishimoto S., Gokoh M., Yanagimoto S., Waku K., et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J Leukoc Biol 76 (2004) 1002-1009
24. Joseph J., Niggemann B., Zaenker K.S., and Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53 (2004) 723-728
25. Ghosh S., Preet A., Groopman J.E., and Ganju R.K. Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 43 (2006) 2169-2179
26. Sacerdote P., Massi P., Panerai A.E., and Parolaro D. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109 (2000) 155-163
27. Lee S.F., Newton C., Widen R., Friedman H., and Klein T.W. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur J Pharmacol 423 (2001) 235-241
28. Carlisle S.J., Marciano-Cabral F., Staab A., Ludwick C., and Cabral G.A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int Immunopharmacol 2 (2002) 69-82
29. Gardner B., Zu L.X., Sharma S., Liu Q., Makriyannis A., Tashkin D.P., et al. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Comm 290 (2002) 91-96
30. Curnock A.P., Sotsios Y., Wright K.L., and Ward S.G. Optimal chemotactic responses of leukemic T cells to stromal cell-derived factor-1 requires the activation of both class 1A and 1B phosphoinositide 3-kinases. J Immunol 170 (2003) 4021-4030
31. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214 (1993) 173-180
32. Wright K., Rooney N., Feeney M., Tate J., Robertson D., Welham M., et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterol 129 (2005) 437-453
33. Klein T.W., Newton C., Larsen K., Liu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol 74 (2003) 486-496
34. McKallip R.J., Lombard C., Fisher M., Martin B.R., Ryu S., Grant S., et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2002) 627-634
35. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 237 (1996) 704-711
36. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., et al. Regulation of extracellular signal regulated kinase by cannabinoids in hippocampus. J Neurosci 23 (2003) 2371-2382
37. Samson M.T., Small-Howard A., Shimoda L.M.N., Koblan-Huberson M., Stokes A.J., and Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 170 (2003) 4953-4962
38. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. Classification of cannabinoid receptors. Pharmacol Rev 54 (2002) 161-202
39. Berdyshev E.V., Schmid P.C., Krebsbach R.J., Hillard C.J., Huang C., Chen N., et al. Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. Biochem J 360 (2001) 67-75
40. Derocq J.M., Bouaboula M., Marchand J., Rinaldi-Carmona M., Segui M., and Casellas P. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. FEBS Lett 425 (1998) 419-425
41. Maccarrone M., Di Rienzo M., Finazzi-Agro A., and Rossi A. Leptin activates the anandamide hydrolase promoter in human T lymphocytes through STAT3. J Biol Chem 278 (2003) 13318-13324
42. Schatz A.R., Lee M., Condie R.B., Pulaski J.T., and Kaminski N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 142 (1997) 278-287
43. Daaka Y., Friedman H., and Klein T.W. Cannabinoid receptor proteins are increased in Jurkat human T-cell line after mitogen activation. J Pharmacol Exp Ther 276 (1996) 776-783
44. Lynn A.B., and Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268 (1994) 1612-1623
45. Carayon P., Marchand J., Dussossoy D., Derocq J.M., Jbilo O., Bord A., et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92 (1998) 3605-3615
46. Deusch E., Kraft B., Nahlik G., Weigl L., Hohenegger M., and Kress H.G. No evidence for direct modulatory effects of delta 9-tetrahydrocannabinol on human polymorphonuclear leukocytes. J Neuroimmunol 141 (2003) 99-103
47. Gokoh M., Kishimoto S., Oka S., Mori M., Waku K., Ishima Y., et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophagelike cells. Biochem J 386 (2005) 583-589
48. Demuth D.G., and Molleman A. Cannabinoid signalling. Life Sci 78 (2006) 549-563
49. Wager-Miller R., Westenbroek, and Mackie K. Dimerization of G protein coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 121 (2002) 83-89
50. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci 77 (2005) 1667-1673
51. Xu W., Filppula S.A., Mercier R., Yaddanapudi S., Pavlopoulos S., Cai, et al. Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. J Pept Res 66 (2005) 138-150
52. Kearn C.S., Blake-Palmer K., Daniel E., Mackie K., and Glass M. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Mol Pharmacol 67 (2005) 1697-1704
53. Hilairet S., Bouaboula M., Carriere D., Le Fur G., and Casellas P. Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 278 (2003) 23731-23737
54. Filppula S., Yaddanapudi S., Mercier R., Xu W., Pavlopoulos S., and Makriyannis A. Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system. J Pept Res 64 (2004) 225-236
55. Percherancier Y., Berchiche Y.A., Slight I., Volkmer-Engert R., Tamamura H., Fujii N., et al. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 280 (2005) 9895-9903
56. Terrillon S., and Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep 5 (2004) 30-34
57. Steele A.D., Szabo I., Bednar F., and Rogers T.J. Interactions between opioid and chemokine receptors: heterologous desensitization. Cytokine Growth Factor Rev 13 (2002) 209-222
58. Kurihara R., Tohyama Y., Matsusaka S., Naruse H., Kinnoshita E., Tsujioka T., et al. Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL-60 cells and human neutrophils. J Biol Chem 281 (2006) 12908-12918
59. Etienne-Manneville S., and Hall A. Rho GTPases in cell biology. Nature 420 (2002) 629-636
60. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272 (1997) 22330-22339
61. Gokoh M., Kishimoto S., Oka S., Metani Y., and Sugiura T. Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. FEBS Lett 579 (2005) 6473-6478
62. Jbilo O., Derocq J.M., Segui M., Le Fur G., and Casellas P. Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60. FEBS Lett 448 (1999) 273-277
63. Smith S.R., Denhardt G., and Terminelli C. The anti-inflammatory activities of cannabinoid receptor ligands in mouse peritonitis models. Eur J Pharmacol 432 (2001) 107-119
64. Maccarrone M., De Petrocellis L., Bari M., Fezza F., Salvati S., Di Marzo V., et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 393 (2001) 321-328
65. Yuan M., Kiertscher S.M., Cheng Q., Zoumalan R., Tashkin D.P., and Roth M.D. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133 (2002) 124-131
66. Herrera B., Carracedo A., Ez-Zaera M., Guzman M., and Velasco G. p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett 579 (2005) 5084-5088
67. Powles T., Poele R.T., Shamash J., Chaplin T., Propper D., Joel S., et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105 (2005) 1214-1221
68. Lombard C., Nagarkatti M., and Nagarkatti P.S. Targeting cannabinoid receptors to treat leukemia: Role of cross-talk between extrinsic and intrinsic pathways in delta 9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 29 (2005) 915-922